Press release
Global Geographic Atrophy Competitive Landscape 2025: Insights Into 25+ Therapies From 23+ Leading Biopharma Companies, analyses DelveInsight
Geographic Atrophy Pipeline
Explore the newest developments, clinical data, and pipeline innovations here: Geographic Atrophy Pipeline Outlook Report - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Geographic Atrophy Pipeline Report
• November 10, 2025: Astellas Pharma Inc. announced a study involving Japanese patients aged 40+ with geographic atrophy. The trial's objective is to evaluate the safety and tolerability of ASP3021, administered as monthly intravitreal injections over 12 months.
• November 7, 2025: Janssen Research & Development LLC initiated a study assessing changes in GA lesion progression in eyes treated with JNJ-81201887 compared to sham control.
• DelveInsight identifies a dynamic R&D environment, with 23+ active Geographic Atrophy companies developing 25+ promising candidates aimed at treating Geographic Atrophy.
• Leading Geographic Atrophy players include Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, NGM Biopharmaceuticals, Annexon, Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences, Stealth BioTherapeutics, Hemera Biosciences, Gyroscope Therapeutics, Eyevensys, Nanoscope Therapeutics, Catalyst Biosciences, Novartis, and others.
• Geographic Atrophy Pipeline therapies showing significant potential include OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007, among others.
Discover the companies driving innovation in GA treatment here: Geographic Atrophy Clinical Trials Assessment - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Geographic Atrophy Pipeline Overview
The report delivers a complete disease overview, a detailed pipeline landscape, and an evaluation of the emerging therapies, emphasizing the critical unmet needs in Geographic Atrophy.
Geographic Atrophy - Disease Summary
Geographic atrophy is an advanced form of age-related macular degeneration (AMD) characterized by progressive loss of macular tissue, including the retinal pigment epithelium, photoreceptors, and choriocapillaris. It typically begins in the perifoveal region and expands toward the fovea, leading to central scotomas and irreversible vision loss. The condition is usually bilateral and steadily progresses over time.
Profiles of Emerging Geographic Atrophy Therapies
IONIS-FB-LRx - Ionis Pharmaceuticals
A ligand-conjugated antisense therapy targeting complement factor B (FB). Excessive activation of the complement cascade, particularly FB, has been linked to complement-mediated disorders including GA. By reducing FB production, IONIS-FB-LRx may modulate disease progression.
Zimura - IVERIC bio
Zimura (avacincaptad pegol) is designed to inhibit complement C5 cleavage, thereby reducing downstream inflammation and cell death. By limiting C5a and C5b formation, the therapy may reduce membrane attack complex (MAC) formation and slow degeneration of retinal pigment epithelial cells in GA.
Track the evolving trial landscape and drug development updates here: Geographic Atrophy Treatment Drugs - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Detailed Insights Offered by the Geographic Atrophy Pipeline Report
• Comprehensive profiles of companies developing GA therapies, along with the number of assets each company is advancing.
• Segmentation of drug candidates by developmental stage-early, mid, and late.
• Evaluation of active, inactive, and discontinued programs.
• Categorization of investigational drugs by route of administration (oral, parenteral, intravitreal, subretinal, topical), mechanism of action, molecular type, and monotherapy vs. combination approach.
• Analysis of partnerships, academic collaborations, licensing deals, and funding activity driving advancement in the GA treatment landscape.
Key Companies in the Geographic Atrophy Pipeline
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, NGM Biopharmaceuticals, Annexon, Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences, Stealth BioTherapeutics, Hemera Biosciences, Gyroscope Therapeutics, Eyevensys, Nanoscope Therapeutics, Catalyst Biosciences, Novartis, and more.
Drug Classification in the Geographic Atrophy Pipeline
Geographic Atrophy By Route of Administration (RoA)
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Geographic Atrophy By Molecule Type
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies
Geographic Atrophy By Product Type
• Monotherapy
• Combination therapy
• Hybrid (Mono/Combination)
Explore market drivers, barriers, and future outlook here:
Geographic Atrophy Market Perspectives - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Geographic Atrophy Pipeline Report
• Coverage- Global
• Geographic Atrophy Companies- Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis and others.
• Geographic Atrophy Therapies- OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007 and others.
• Geographic Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Geographic Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay informed on emerging GA therapies and competitive intelligence: Geographic Atrophy Emerging Drugs & Major Players - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Geographic Atrophy Competitive Landscape 2025: Insights Into 25+ Therapies From 23+ Leading Biopharma Companies, analyses DelveInsight here
News-ID: 4297295 • Views: …
More Releases from DelveInsight Business Research
Giant-Cell Arteritis Market Outlook 2034: Key Epidemiological Shifts, Emerging D …
DelveInsight's latest report, "Giant-Cell Arteritis Market Insight, Epidemiology, and Market Forecast - 2034," offers a comprehensive analysis of Giant-Cell Arteritis (GCA), covering historical and projected epidemiology as well as market trends for approved and emerging therapies across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Gain a deep understanding of the evolving Giant-Cell Arteritis landscape. Download DelveInsight's full report to explore market dynamics, pipeline developments,…
Osteoarthritis Competitive Landscape 2025: Over 100 Companies Driving a Robust P …
DelveInsight's latest analysis reveals that the global Osteoarthritis (OA) pipeline includes more than 100 companies actively developing 110+ therapeutic candidates, spanning diverse clinical stages. The comprehensive evaluation covers clinical trials, therapeutic classes, mechanisms of action, routes of administration, and ongoing R&D developments.
DelveInsight's report, "Osteoarthritis Pipeline Insight, 2025," delivers an in-depth overview of the current clinical landscape and future growth opportunities across the global Osteoarthritis market. The study offers extensive commercial…
Narcolepsy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Juvenile Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Juvenile Rheumatoid Arthritis pipeline constitutes 8+ key companies continuously working towards developing 10+ Juvenile Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Juvenile Rheumatoid Arthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Juvenile Rheumatoid…
More Releases for Geographic
Geographic Information System (GIS) Software Global Market Report 2024 - Geograp …
"The Business Research Company recently released a comprehensive report on the Global Geographic Information System (GIS) Software Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The…
Cybersecurity Market Regional Analysis | Evaluating Geographic Trends
Cybersecurity Market Scope and Overview
In the digital era, where information is the new currency, cybersecurity emerges as a paramount concern for individuals, businesses, and governments alike. With the exponential growth of cyber threats, the global Cybersecurity Market has witnessed a surge in demand for innovative solutions and services to safeguard sensitive data and critical infrastructure. This report delves into a comprehensive analysis of the cybersecurity market, covering key players, market…
Geographic Information System - Comprehensive Analysis
GIS is used to power millions of decisions every day all over the world, such as examining crime patterns, pinpointing novel store locations, directing in-car navigation, and predicting and forecasting the weather, among others. The growing demand for location-based analytics among businesses to enhance operational efficiency and improve decision-making is driving the market growth. Similarly, the necessity to combine traditional data with three-dimensional data to get valuable insights from location-based…
Automobile Accessories Market: Charting New Geographic Territory
An extensive analysis of the Automobile Accessories market strategy of the leading companies in the precision of import/export consumption, supply and demand figures, cost, price, revenue and gross margins. The report starts by an introduction about the company profiling and a comprehensive review about the strategy concept and the tools that can be used to assess and analyze strategy. It also analyzes the company’s strategy in the light of Porter’s…
Geographic Atrophy - Pipeline Review, H2 2018 - ResearchByMarkets.com
"Geographic Atrophy - Pipeline Review, H2 2018", provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape.
Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract…
MapsOfWorld.com partners with National Geographic Maps
MapsOfWorld.com has proudly partnered with National Geographic Maps to sell National Geographic maps and atlases in the United States. All wall maps are available at an initial discount of 15%, along with additional discounts on bulk items ordered by corporations and schools. Range of products available for sale include: paper and laminated wall maps, mural (wall paper) maps, travel maps and atlases. Wall maps are available in National Geographic’s three…
